LoginSignup
Hikma Pharma logo

Hikma Pharma

Stock
Stock
ISIN: GB00B0LCW083
Ticker: HIK
GB00B0LCW083
HIK

Price

Price

CHART BY

Historical dividends and forecast

All dividend data

Hikma Pharma has so far distributed $0.48 in 2026. The next dividend will be paid on 17.09.2026

$0.383

CHART BY

Frequently asked questions

The market capitalization of Hikma Pharma is 3.17B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
The Price-to-Earnings (P/E) ratio (TTM) for Hikma Pharma is 11.43. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.
Hikma Pharma's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $1.339. EPS indicates the company's profitability on a per-share basis.
Currently, 13 analysts cover Hikma Pharma's stock, with a consensus target price of 27.09. Analyst ratings provide insights into the stock's expected performance.
Over the trailing twelve months, Hikma Pharma reported a revenue of 2.55B.
Yes, Hikma Pharma is paying dividends. The next payment is scheduled for 17.09.2026, with an expected amount of .
Hikma Pharma's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is 668.23M. EBITDA measures the company's overall financial performance.
Hikma Pharma has a free cash flow of 110.42M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
Hikma Pharma employs approximately 9,400 people. It operates in the Health Care sector, specifically within the Generic Pharmaceuticals industry.
The free float of Hikma Pharma is 134.42M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap 
3.17B
EPS (TTM) 
$1.339
Free Float 
134.42M
P/E ratio (TTM) 
11.43
Revenue (TTM) 
2.55B
EBITDA (TTM) 
668.23M
Free Cashflow (TTM) 
110.42M

Pricing

1D span
$20.24$20.99
52W span
$15.91$25.03

Analyst Ratings

The price target is 27.09 and the stock is covered by 13 analysts.

Buy

12

Hold

1

Sell

0

Information

Hikma Pharmaceuticals Plc engages in developing, manufacturing, and marketing branded and non-branded generic pharmaceutical products. It operates through the following segments: Branded, Injectables, and Rx. The Branded segment sells branded generics and in-licensed patented products in the Middle East and North Africa. The Injectables segment includes generic injectable products distributed globally and primarily used in hospitals. The Rx segment includes oral, respiratory and other generic and specialty products supplied to the North American retail market, leveraging state-of-the-art manufacturing facility in Columbus, Ohio. The company was founded by Samih Taleb Darwazah in 1978 and is headquartered in London, the United Kingdom.

Employees
9,400
Industries
Generic Pharmaceuticals
Sector
Health Care

Identifier

ISIN
GB00B0LCW083
Primary Ticker
HIK

Knockouts

Real-time data from LSX · Fundamentals & EOD data from FactSet
Join the conversation
Sign upLogin